Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 9INDUSTRY 7NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Lung Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Melanoma 8Carcinoma, Non-Small-Cell Lung 6Urinary Bladder Neoplasms 5Ovarian Neoplasms 4Endometrial Neoplasms 4Carcinoma, Transitional Cell 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Mouth Neoplasms 3Leukemia, Myeloid, Acute 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma 3Breast Neoplasms 3Urogenital Neoplasms 2Sezary Syndrome 2Pancreatic Neoplasms 2Neoplasms 2Mycosis Fungoides 2Mesothelioma, Malignant 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Glioma 2Colorectal Neoplasms 2Carcinosarcoma 2Carcinoma, Renal Cell 2Carcinoma, Merkel Cell 2Biliary Tract Neoplasms 2

Interventions

Magnetic Resonance Spectroscopy 10Cisplatin 10Specimen Handling 8Radiotherapy 6Platinum 61,2-diaminocyclohexaneplatinum II citrate 6Paclitaxel 5Radiotherapy, Intensity-Modulated 4Fluorodeoxyglucose F18 4Biopsy 4Radiation 3Nivolumab 3Fluorouracil 3Carboplatin 3fludarabine phosphate 2fludarabine 2aldesleukin 2Taxes 2Radiosurgery 2Immunoglobulin G 2Gemcitabine 2Docetaxel 2Disulfides 2Cyclophosphamide 2Cetuximab 2(225)Ac-DOTA-c(RGDyK) 2veliparib 1peposertib 1pembrolizumab 1ipatasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Oropharyngeal Neoplasms × pembrolizumab × Clear all
NCT04576091 2024-12-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
7 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡